Versant Venture Management
San Francisco, CAfiles as Versant Venture Management, LLC
$163m in 8 US stocks at the end of 30 June 2026. The top 10 are 100.0% of the money. It changed about 10.8% of the portfolio this quarter.
Value
$163m
Stocks
8
Top 10 share
100.0%
Turnover
10.8%
What changed this quarter
New
Bought for the first time this quarter.
None this quarter.
Added
Bought more of a stock they already held.
None this quarter.
Cut
Sold some of their stake.
- Jade BiosciencesJBIO13.6% of the fund-35%
Sold out
Sold their entire stake.
None this quarter.
Holdings
- Skye Bioscience
- Share
- 0.9%
- Value
- $1m
- Shares
- 2,007,704
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Monte Rosa TherapeuticsGLUE | 47.3% | $77m | 3,180,780 | Held |
| Century TherapeuticsIPSC | 18.3% | $30m | 12,166,109 | Held |
| Jade BiosciencesJBIO | 13.6% | $22m | 991,783 | -35% |
| LENZ TherapeuticsLENZ | 9.3% | $15m | 2,656,888 | Held |
| Contineum TherapeuticsCTNM | 5.5% | $9m | 542,628 | Held |
| CRISPR Therapeutics AGCRSP | 5.0% | $8m | 148,831 | Held |
| Skye Bioscience | 0.9% | $1m | 2,007,704 | Held |
| Tempest TherapeuticsTPST | 0.2% | $299,447 | 269,772 | Held |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 98.0% since 30 June 2025.
Where the money is
Health care99.1%
Other0.9%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.